版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Apatinib (YN968D1) reverses multidrug resistance by inhibiting the function of multiple ATP-binding cassette transporters Yanjun Mi, Liwu FuState Key Laboratory of oncology in southern China, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, ChinaEmail: FBackgroundA successful cancer chemoth
2、erapy is limited by multidrug resistance (MDR). The major inducers of MDR are the ABC transporters, such as ABCB1 (anthracyclins, vinca alkaloids, taxanes, and epipodophyllotoxins), ABCG2 (mitoxantrone, anthracyclins, topoisomerase I inhbitors, methotrexate).Combination of modulator with conventiona
3、l chemotherapeutic drugs to restore the sensitivity of MDR cells is a main strategy for overcoming MDR.Tyrosine kinase inhibitors (TKIs) belong to a new class of anticancer drugs.TKIs including lapatinib, erlotinib and sunitinib, have been shown to overcome ABC transporters-mediated MDR in cancer ce
4、lls.Apatinib (YN968D1) is an oral small-molecule TKI that targets VEGFR-2, RET, c-Kit and c-Src tyrosine kinases. It is conceivable that apatinib may inhibit functions of ABC transporters by binding to their ATP-binding sites.BackgroundCytotoxicity of apatinib alone in all experimental cell linesMor
5、e than 85% of cells were viable at concentrations of apatinib up to 3.0 M in all experimental cells.ABCB1ABCB1ABCG2Apatinib reversed MDR in vitroCompoundsIC50 SD (M) (fold-reversal)S1S1-M1-80 (ABCG2)Mitoxantrone0.194 0.027(1.00)13.651 0.922(1.00)+ 0.75 M Apatinib0.196 0.041(0.98)6.434 0.478*(2.12)+
6、1.5 M Apatinib0.185 0.058(1.05)2.070 0.621*(6.59)+ 3.0 M Apatinib0.136 0.067(1.42)1.188 0. 495*(11.5)+ 2.5 M FTC0.188 0.011(1.03)0.892 0.056*(15.3)Topotecan0.262 0.042(1.00)10.281 0.455(1.00)+ 0.75 M Apatinib0.264 0.022(0.99)4.089 0.026*(2.51)+ 1.5 M Apatinib0.247 0.017(1.05)2.037 0.083*(5.04)+ 3.0
7、M Apatinib0.196 0.055(1.33)1.188 0.055*(8.65)+ 2.5 M FTC0.254 0.016(1.02)0.745 0.068*(13.8)Cisplatin12.811 1.181(1.00)12.092 1.322(1.00)+ 3.0 M Apatinib12.280 1.990(1.04)12.143 1.452(1.00)HL60HL60/ADR(ABCC1)Doxorubicin 0.036 0.002(1.00)5.704 0.378(1.00)+ 0.75 M Apatinib 0.035 0.002(1.04)5.493 0.289(
8、1.03)+ 1.5 M Apatinib 0.037 0.002(0.97)5.528 0.515(1.02)+ 3.0 M Apatinib 0.033 0.004(1.09)5.719 0.595(1.00)Apatinib reversed MDR in vitroCompounds IC50 SD (M) (fold-reversal)HEK293/pcDNA3.1HEK293/ABCG2-R2HEK293/ABCB1 Mitoxantrone 0.0569 0.0035(1.00) 1.3460 0.3143(1.00) 0.1381 0.0274(1.00) + 3 M Apat
9、inib 0.0349 0.0097(1.63) 0.0655 0.0199*(20.55) 0.0616 0.0357*(2.24) + 3 M FTC 0.0528 0.0093(0.98) 0.0687 0.0126*(19.59)- + 3 M PSC833 0.0543 0.0069(1.04)- 0.0688 0.0459*(2.01) SN-38 0.0073 0.0003(1.00) 0.1530 0.1636(1.00)- + 3 M Apatinib 0.0045 0.0009(1.62) 0.0079 0.0021*(19.37)- + 3 M FTC 0.0050 0.
10、0003(1.46) 0.0085 0.0016*(18.00)- Vincristine 0.0437 0.0022(1.00- 0.6405 0.0349(1.00) + 3 M Apatinib 0.0335 0.0039(1.30)- 0.1792 0.0485*(3.57) + 10 M Verapamil 0.0450 0.0003(0.97)- 0.0514 0.0025*(12.46) Doxorubicin 0.0724 0.0054(1.00)- 1.0821 0.5424(1.00) + 3 M Apatinib 0.0512 0.0033(1.41)- 0.3168 0
11、.0045*(3.42) + 10 M Verapamil 0.0957 0.0142(0.77)- 0.0964 0.0153*(11.23) Cisplatin 1.8240 0.4728(1.00) 1.6521 0.3892(1.00) 1.4899 0.5321(1.00) + 3 M Apatinib 1.5256 0.3717(1.19) 1.4193 0.4820(1.16) 1.6479 0.2402(0.90) Effect of apatinib on the accumulation of doxorubicin Effect of apatinib on the ac
12、cumulation of rhodamine 123ApatinibExpression of ABCB1 and ABCG2ABCB1 and ABCG2 ATPase activityReverse ABCB1- and ABCG2-mediated MDR Intracellular accumulation of drugs in the MDR cells Effect of apatinib on the expression of ABCB1 and ABCG2Effect of apatinib on the expression of ABCB1 and ABCG2Effe
13、ct of apatinib on ABCB1 and ABCG2 ATPase activity950nmol/L10-12nmol/LEffect of apatinib on the phosphorylation of AKT and ERK1/2 ApatinibABCB1 and ABCG2 ATPase activityExpression of ABCB1 and ABCG2MDRIntracellular accumulation of drugs in the MDR cells ReverseBlockade of AKT and ERK1/2 activation AcknowledgmentsWe like to thank Professor Su
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年大理州永平县审计局城镇公益性岗位人员招聘(2人)考试备考试题及答案解析
- 护理体位摆放案例分析
- 2026甘肃庆阳市西峰区学院路实验学校人才储备考试参考试题及答案解析
- 2026年福建省泉州市安溪县凤城中学招聘教师考试参考试题及答案解析
- 2026广西百色平果市协力初级中学教师招聘2人考试参考试题及答案解析
- 2026浙江台州玉环农商银行寒假实习生招聘考试备考题库及答案解析
- 2026安徽宿州市萧县融资担保有限公司选调4人考试备考题库及答案解析
- 2026年武汉经开区教育系统校园专项招聘教师50人考试备考试题及答案解析
- 快速成型加工技术:智能制造时代的创新引擎
- 井研县中医医院医共体关于2025年下半年公开招聘编外护理人员的备考题库完整答案详解
- 《机器学习》课件-第7章 神经网络与深度学习
- 生物安全培训试题(含答案)
- 分局辅警服装购置项目方案投标文件(技术标)
- 滑行工具好玩也危险
- 2025-2030中国智能家居系统配置服务技术人才缺口评估报告
- 护士肺功能室进修汇报
- 员工工时管控方案(3篇)
- 监控证考试题库及答案
- GB/T 33474-2025物联网参考体系结构
- 静脉输液十二种并发症及防治措施
- 投资境外股权管理办法
评论
0/150
提交评论